IN2014MN01594A - - Google Patents

Info

Publication number
IN2014MN01594A
IN2014MN01594A IN1594MUN2014A IN2014MN01594A IN 2014MN01594 A IN2014MN01594 A IN 2014MN01594A IN 1594MUN2014 A IN1594MUN2014 A IN 1594MUN2014A IN 2014MN01594 A IN2014MN01594 A IN 2014MN01594A
Authority
IN
India
Prior art keywords
agent
strain
mtb
allergic
asthma
Prior art date
Application number
Other languages
English (en)
Inventor
Iglesias Pere Joan Cardona
Riera Isabel Amat
Moreno Blanca Reyes
Fabregat Maria Mercè Amat
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of IN2014MN01594A publication Critical patent/IN2014MN01594A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1594MUN2014 2012-01-12 2012-01-12 IN2014MN01594A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/000353 WO2013104943A1 (fr) 2012-01-12 2012-01-12 Vaccin mycobacterium tuberculosis-complex (mtb-c) contre l'asthme

Publications (1)

Publication Number Publication Date
IN2014MN01594A true IN2014MN01594A (fr) 2015-05-08

Family

ID=45852617

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1594MUN2014 IN2014MN01594A (fr) 2012-01-12 2012-01-12

Country Status (15)

Country Link
US (1) US9682042B2 (fr)
EP (1) EP2802345B1 (fr)
CN (1) CN104411326B (fr)
AU (1) AU2012365465B2 (fr)
BR (1) BR112014017217B1 (fr)
CA (1) CA2861074C (fr)
DK (1) DK2802345T3 (fr)
ES (1) ES2670493T3 (fr)
IN (1) IN2014MN01594A (fr)
NO (1) NO2802345T3 (fr)
PL (1) PL2802345T3 (fr)
PT (1) PT2802345T (fr)
RU (1) RU2602771C2 (fr)
WO (1) WO2013104943A1 (fr)
ZA (1) ZA201405107B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (zh) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 一种可变形脂质体的制备方法,及其制备的可变性脂质体
RU2652752C1 (ru) * 2017-06-15 2018-04-28 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ лечения бронхиальной астмы
EP3797791A1 (fr) * 2019-09-26 2021-03-31 Universidad De Zaragoza Efficacité thérapeutique par administration pulmonaire de mycobactéries atténuées vivantes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900378A3 (en) 1995-02-22 1999-11-29 Adcock Ingram Ltd A method for the isolation and purification of lipid cell-wall components
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
BR0103887C1 (pt) 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
EP1761662A4 (fr) 2004-07-01 2010-02-03 Univ California Proteomique a grand debit
PT2426141E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
WO2007022152A2 (fr) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Corps nanoparticulaires lipides contenant des antigenes servant de vaccins anticancereux
US9393215B2 (en) 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US20090081284A1 (en) * 2006-04-20 2009-03-26 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
HUE031951T2 (en) 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
EP2421557B1 (fr) 2009-04-24 2018-12-05 Statens Serum Institut Vaccin contre la tuberculose tb pour prévenir une réactivation
SG190937A1 (en) 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition

Also Published As

Publication number Publication date
CA2861074C (fr) 2018-11-06
AU2012365465A1 (en) 2014-08-21
CA2861074A1 (fr) 2013-07-18
EP2802345B1 (fr) 2018-03-07
DK2802345T3 (en) 2018-04-30
ES2670493T3 (es) 2018-05-30
AU2012365465B2 (en) 2017-05-18
PL2802345T3 (pl) 2018-08-31
NO2802345T3 (fr) 2018-08-04
CN104411326B (zh) 2018-02-02
US20150132364A1 (en) 2015-05-14
PT2802345T (pt) 2018-04-24
EP2802345A1 (fr) 2014-11-19
WO2013104943A1 (fr) 2013-07-18
ZA201405107B (en) 2020-11-25
RU2014133042A (ru) 2016-02-27
RU2602771C2 (ru) 2016-11-20
BR112014017217A8 (pt) 2017-07-04
BR112014017217B1 (pt) 2023-01-17
US9682042B2 (en) 2017-06-20
CN104411326A (zh) 2015-03-11
BR112014017217A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
EA201690541A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
WO2014045254A3 (fr) Lignée c de coronavirus bêta humains et identification de la peptidase dipeptidylique n-terminale en tant que récepteur viral
HK1212249A1 (en) Bioconjugates comprising modified antigens and uses thereof
MX2013003817A (es) Supresion de una respuesta inmunologica de hipersensibilidad con antigeno no relacionado derivado de material de fuente de alergeno.
IN2015DN00376A (fr)
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
WO2014127917A8 (fr) Combinaison d'une vaccination et de l'inhibition de la voie de pd-1
IN2015KN00414A (fr)
WO2014121298A3 (fr) Méthodes de peuplement du tractus gastro-intestinal
WO2013059559A3 (fr) Composés et procédés d'amélioration des réponses immunitaires innées
MX2016010373A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
WO2013098655A3 (fr) Antigènes et vaccins dirigés contre des entérovirus humains
MX381173B (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
WO2012015986A3 (fr) Dérivés substitués de bioxopipéridinyl phtalimide
WO2014016548A3 (fr) Composition pharmaceutique
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
WO2013036610A3 (fr) Compositions comprenant le mg53 et procédés de traitement et de prévention de lésions au niveau des voies respiratoires
WO2014205199A3 (fr) Compositions et méthodes de potentialisation de la réponse immunitaire, de stimulation de l'immunothérapie et d'augmentation de la puissance d'un vaccin
MX2015006370A (es) Suplementos herbales y metodos para utilizar los mismos.
WO2015054678A3 (fr) Vaccin thérapeutique contre le papillomavirus humain
WO2014052780A3 (fr) Compositions et procédés d'utilisation d'un composé de lutte contre l'inappétence
SG10201807682PA (en) Methods of Treating or Preventing Respiratory Conditions
SG10201908089VA (en) Novel dosing regimens of celgosivir for the treatment of dengue
WO2014074817A3 (fr) Vaccins de mannheimia haemolytica atténués et procédés de fabrication et d'utilisation